

KCD INDUSTRIES INDIA LIMITED

CIN: L70100MH1985PLC01881

Regd. Unit No 101, 1st Floor, KCD Jogeshi Ewa, Road No.1, Jogeshwari (East), Mumbai - 400 060
Phone: 9137322030 Email: compliance@kcdindustries.com Web: www.kcdindustries.com

Extracts of the Statement of Un-audited Financial Results for the Quarter Ended 30th June 2024

Particulars	Standalone		Consolidated	
	Quarter Ended on		Quarter Ended on	
	30.06.2024	30.06.2023	30.06.2024	30.06.2023
	Un-audited	Un-audited	Un-audited	Un-audited
Total income from operations (net)	660.857	851.055	660.857	851.055
Net Profit/(Loss) for a period (before tax, Exceptional and/or Extraordinary items)	19.329	65.374	19.329	65.374
Net Profit/(Loss) for a period before tax (after Exceptional and/or Extraordinary items)	19.329	65.374	19.329	65.374
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	13.299	65.374	13.299	65.374
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	13.299	65.374	13.299	65.374
Equity Share Capital	371.429	100	371.429	100
Earnings Per Share (of Rs.1 each) (for continuing and discontinued operations) -				
1. Basic:	0.047	0.654	0.047	0.654
2. Diluted:	0.047	0.654	0.047	0.654

Note:
The above result is an extract of the detailed format of Un-audited Standalone and Consolidated Financial Results for the quarter ended 30th June 2024 filed with Stock Exchange under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly results is available on website of Stock Exchange.

Figures of the previous year have been re-grouped/ re-arranged/ re-classified wherever considered necessary.
For KCD Industries India Limited
Sd/-
Rajiv Darji
Managing Director
DIN: 02088219
Place: Mumbai
Date: 12th August 2024

POST OFFER ADVERTISEMENT UNDER REGULATION 18 (12) OF SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011, AND AMENDMENTS THERETO FOR THE ATTENTION OF THE PUBLIC SHAREHOLDERS OF

FOODS AND INNS LIMITED

CIN: L55200MH1967PLC013837

Registered Office: Udyog Bhavan, 2nd Floor 29 Walchand Hirachand Marg, Ballard Estate, Mumbai City, Mumbai, Maharashtra, India-400038.

Corporate Office: J. N. Heredia Marg, Hamilton House, 3rd floor, Ballard Estate, Mumbai, Maharashtra, India, 400038

Contact No.: +91 22 2261 3102

Email ID: cs@foodsandinns.com. Website: https://www.foodsandinns.com/

Open Offer for acquisition of up to 1,90,79,617 fully paid-up equity shares of face value of ₹1 each representing 26.00% of the Expanded Voting Share Capital of Foods and Inns Limited ("Target Company") at a price of ₹147 per equity share from the public shareholders of the Target Company by Raymond Simkins ("Acquirer 1") and Milan Bhupendra Dalal ("Acquirer 2") (hereinafter Acquirer 1 and Acquirer 2 are collectively referred to as "Acquirers"), along with Borgos Multitrade LLP (deemed to be Person Acting In Concert with Acquirer 2 or "PAC", for the purpose of the Open Offer) pursuant to and in compliance with Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and amendments thereto ("SEBI (SAST) Regulations, 2011") ("Open Offer" or "Offer").

This post-offer advertisement ("Post-Offer Advertisement") is issued by Inga Ventures Private Limited and Pioneer Investcorp Limited ("Managers to the Open Offer"), in respect of the Open Offer, for and on behalf of the Acquirers along with the PAC to the Public Shareholders of the Target Company, pursuant to and in compliance with Regulation 18 (12) of SEBI (SAST) Regulations, 2011. The detailed public statement dated April 16, 2024 ("Detailed Public Statement" or "DPS") with respect to the aforementioned Offer was published on April 18, 2024 in the following newspapers:

Newspaper	Language	Edition(s)
Financial Express	English	All Editions
Jansatta	Hindi	All Editions
Pratahkal	Marathi	Marathi Edition

The Shareholders of the Target Company are requested to kindly note the following information with respect to the Open Offer:

1) Name of the Target Company	: Foods and Inns Limited
2) Name of the Acquirer(s) and PAC	: 1) Raymond Simkins : Acquirer 1 2) Milan Bhupendra Dalal : Acquirer 2 3) Borgos Multitrade LLP : PAC
3) Name of the Manager to the Offer	: 1) Inga Ventures Private Limited 2) Pioneer Investcorp Limited
4) Name of the Registrar to the Offer	: Link Intime India Private Limited
5) Offer Details:	
a) Date of Opening of the Offer	: Tuesday, July 23, 2024
b) Date of Closure of the Offer	: Monday, August 05, 2024
6) Date of Completion of Payment of Consideration and communication of Rejection/Acceptance	: Friday, August 09, 2024

7) Details of Acquisition:

Sr. No.	Particulars	Proposed in the Letter of Offer ⁽¹⁾	Actuals ⁽¹⁾
7.1	Offer Price (in ₹)	₹147 per Equity Share	₹147 per Equity Share
7.2	Aggregate number of Shares tendered	Up to 1,90,79,617 ⁽²⁾	5,00,712
7.3	Aggregate number of Shares accepted	Up to 1,90,79,617 ⁽²⁾	5,00,712
7.4	Size of the Offer (Number of Equity Shares multiplied by Offer Price per Equity Share)	₹280,47,03,699 ⁽³⁾	₹7,36,04,664 ⁽³⁾
7.5	Shareholding of the Acquirers before Public Announcement		
	• Number	81,28,910	81,28,910
	• % of Expanded Voting Share Capital	11.08%	11.08%
7.6	Shares acquired by way of Agreement / Preferential Allotment	Nil	Nil
	• Number		
	• % of Expanded Voting Share Capital		
7.7	Shares Acquired by way of Open Offer		
	• Number	1,90,79,617	5,00,712 ⁽⁴⁾
	• % of Expanded Voting Share Capital	26%	0.68%
7.8	Shares acquired after Detailed Public Statement ("DPS")	Nil	Nil
	• Number		
	• % of Expanded Voting Share Capital		
7.9	Post Offer Shareholding of the Acquirers		
	• Number	81,28,910	86,29,622
	• % of Expanded Voting Share Capital	11.08%	11.76%
7.10	Pre & Post Offer Shareholding of the Public (other than Acquirers and PAC):		
	• Number	5,48,83,422	5,48,83,422
	• % of Expanded Voting Share Capital	74.79%	74.79% ⁽¹⁾

⁽¹⁾ Percentages disclosed in the table above are computed basis the Expanded Voting Share Capital.
⁽²⁾ Assuming full acceptance in the Open Offer.
⁽³⁾ Excludes Brokerage and other charges.
⁽⁴⁾ All the Equity Shares tendered and acquired in the Offer were in dematerialized form and none were in physical form.

8) The Acquirers, the PAC and its designated Partners accept full responsibility for the information contained in this Post Offer Advertisement and also for the obligations under SEBI (SAST) Regulations, 2011.

9) A copy of this Post Offer Advertisement will be available on the websites of SEBI (www.sebi.gov.in), BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and will be dispatched to the registered office of the Target Company.

Capitalized terms used in this Post-Offer Advertisement, but not defined herein, shall have the same meanings assigned to such terms in the Letter of Offer dated July 10, 2024.

Issued by Managers to the Offer on behalf of the Acquirers and the PAC:

INGA
Inga Ventures Private Limited
1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli, Andheri (East), Mumbai, 400 069, Maharashtra, India
Tel. No.: +91 22 68510808
Contact Person: Kavita Shah
E-Mail: foodsandinns.co@ingaventures.com
SEBI Regn No.: INM000012698

PINC
Pioneer Investcorp Limited
1218, 12th Floor, Maker Chambers V, Nariman Point, Mumbai, 400021
Tel. No.: +91 22 66186633;
Contact Person: Varun Jain
E-Mail: projectfood@pinc.co.in
SEBI Regn No.: INM00002988

For and on behalf of the Acquirers and PAC

Sd/-
Milan Bhupendra Dalal
("Acquirer 2")
Date : August 14, 2024
Place : Mumbai



GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026;
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off. Western Express Highway, Andheri (E), Mumbai - 400099.
Phone No: +91 22 4018 9999 Fax No.: +91 22 4018 9986; Website: www.glenmarkpharma.com; Email: complianceofficer@glenmarkpharma.com; CIN: L24299MH1977PLC019982

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2024

(All amounts in million of Indian Rupees, unless otherwise stated)

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter ended	Quarter ended	Quarter ended	Year ended	Quarter ended	Quarter ended	Quarter ended	Year ended
		30/06/2024	31/03/2024	30/06/2023	31/03/2024	30/06/2024	31/03/2024	30/06/2023	31/03/2024
	(Unaudited)	(Refer note 7)	(Unaudited)	(Audited)	(Unaudited)	(Refer note 7)	(Unaudited)	(Audited)	
I	Revenue from operations	22,968.75	20,771.32	20,980.62	76,497.61	32,233.02	30,160.07	29,984.72	1,16,354.56
	(a) Net sales	326.62	710.91	463.22	2,413.58	208.84	469.45	375.94	1,776.41
	(b) Other operating income	23,295.37	21,482.23	21,443.84	78,911.19	32,441.86	30,629.52	30,360.66	1,18,130.97
II	Other income	556.48	7,862.70	493.61	11,680.24	314.92	7,731.65	197.22	8,399.94
III	Total income (I + II)	23,851.85	29,344.93	21,937.45	90,591.43	32,756.78	38,361.17	30,557.88	1,26,530.91
IV	Expenses								
	(a) Cost of materials consumed	6,481.09	6,854.51	7,967.56	29,904.11	6,857.74	7,543.09	8,302.54	31,578.22
	(b) Purchases of stock-in-trade	889.85	816.58	821.71	3,227.82	3,600.26	2,108.04	4,184.25	14,511.70
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	569.24	(21.20)	(230.84)	(1,030.70)	642.82	304.15	(608.82)	(1,956.22)
	(d) Employee benefits expense	3,844.03	3,377.45	3,344.66	14,347.75	7,104.40	7,009.55	6,812.73	28,681.43
	(e) Finance costs	153.49	833.85	619.34	2,771.10	395.82	1,485.59	1,116.08	5,159.69
	(f) Depreciation, amortisation and impairment expense	530.87	524.01	487.52	2,021.62	1,177.89	1,513.37	1,420.40	5,819.06
	(g) Other expenses	5,200.14	5,480.41	4,690.79	20,045.58	8,354.51	8,621.26	7,296.44	33,362.53
	Total expenses (IV)	17,668.71	17,865.61	17,700.74	71,287.28	28,133.44	28,585.05	28,523.62	1,17,156.41
V	Profit/(loss) before exceptional items and tax (III - IV)	6,183.14	11,479.32	4,236.71	19,304.15	4,623.34	9,776.12	2,034.26	9,374.50
VI	Exceptional items (gain)/ loss (Refer note 5)	-	(51,469.13)	316.29	(50,703.31)	-	4,467.85	520.23	9,009.55
VII	Profit/(loss) before tax from continuing operations (V - VI)	6,183.14	62,948.45	3,920.42	70,007.46	4,623.34	5,308.28	1,514.03	364.95
VIII	Tax expense -								
	Current tax	1,079.84	10,553.79	385.65	10,499.92	1,468.82	10,581.74	567.23	11,155.52
	Deferred tax	565.99	6,257.71	818.21	7,834.63	(247.86)	7,112.99	570.02	7,517.93
IX	Profit/(loss) after tax for the period from continuing operations (VII - VIII)	4,537.31	46,136.95	2,716.56	51,672.91	3,402.38	(12,386.45)	376.78	(18,308.50)
X	Profit/(loss) for the period from continuing operations attributable to:								
	- Non-controlling interests	-	-	-	-	(0.29)	40.10	231.94	681.46
	- Owners of the Company	4,537.31	46,136.95	2,716.56	51,672.91	3,402.67	(12,426.55)	144.84	(18,989.96)
XI	Profit/(loss) before tax from discontinued operations	-	-	-	-	-	310.80	1,820.04	5,326.92
XII	Tax expense of discontinued operations:								
	Current tax	-	-	-	-	-	72.73	435.99	1,284.32
	Deferred tax	-	-	-	-	-	(5.69)	29.55	69.32
XIII	Profit/(loss) after tax for the period from discontinued operations (XI - XII)	-	-	-	-	-	243.76	1,354.50	3,973.28
XIV	Profit/(loss) for the period from discontinued operations attributable to:								
	- Non-controlling interests	-	-	-	-	-	-	-	-
	- Owners of the Company	-	-	-	-	-	243.76	1,354.50	3,973.28
XV	Profit/(loss) after tax for the period from continuing and discontinued operations (IX + XIII)	4,537.31	46,136.95	2,716.56	51,672.91	3,402.38	(12,142.69)	1,731.28	(14,335.22)
XVI	Profit/(loss) for the period from continuing and discontinued operations attributable to:								
	- Non-controlling interests	-	-	-	-	(0.29)	40.10	231.94	681.46
	- Owners of the Company	4,537.31	46,136.95	2,716.56	51,672.91	3,402.67	(12,182.79)	1,499.34	(15,016.68)
XVII	Other comprehensive income from continuing operations								
	A (i) Items that will not be reclassified to profit or loss	(12.52)	(9.74)	(7.50)	(73.14)	(7.01)	(94.10)	(5.52)	(163.06)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.37	9.44	2.23	25.56	2.79	26.65	2.23	42.75
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	60.50	846.57	(564.37)	(399.03)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	(1.36)	(20.13)	6.80	(79.97)
XVIII	Total comprehensive income from continuing operations for the period/ year	4,529.16	46,136.65	2,711.29	51,625.33	3,457.30	(11,627.47)	(184.08)	(18,907.81)
XX	Other comprehensive income from discontinued operations for the period/ year	-	-	-	-	-	(0.19)	(0.73)	(56.23)
XXI	Total comprehensive income from discontinued operations for the period/ year (XIII + XIX)	-	-	-	-	-	243.57	1,353.77	3,917.05
XXII	Other comprehensive income for the period/ year from continuing and discontinued operation (XVII + XIX)	(8.15)	(0.30)	(5.27)	(47.58)	54.92	758.79	(561.59)	(655.53)
XXIII	Total comprehensive income for the period/ year from continuing and discontinued operation (XVIII + XX)	4,529.16	46,136.65	2,711.29	51,625.33	3,457.30	(11,383.89)	1,169.69	(14,990.76)
XXIV	Total comprehensive income attributable to:								
	- Non-controlling interests	-	-	-	-	(0.26)	40.22	231.98	672.00
	- Owners of the Company	4,529.16	46,136.65	2,711.29	51,625.33	3,457.56	(11,424.11)	937.71	(15,662.76)
XXV	Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.19	282.19	282.17	282.19	282.19	282.19	282.17	282.19
XXVI	Other equity (other than revaluation reserve)	-	-	-	-	-	-	-	-
XXVII	Earning per share for continuing operations (EPS) (not annualised except for the year ended 31 March)								
	Basic (in Rupees)	12.06	(44.04)	0.51	(67.30)	12.06	(44.04)	0.51	(67.30)
	Diluted (in Rupees)	-	-	-	-	-	-	-	-
XXVIII	Earning per share for discontinued operations (EPS) (not annualised except for the year ended 31 March)								
	Basic (in Rupees)	-	0.86	4.80	14.08	-	0.86	4.80	14.08
	Diluted (in Rupees)	-	0.86	4.80	14.08	-	0.86	4.80	14.08
XXIX	Earning per share for continuing and discontinued operations (EPS) (not annualised except for the year ended 31 March)								
	Basic (in Rupees)	16.08	163.50	9.63	183.13	12.06	(43.17)	5.31	(53.22)

आरोपीला वाचवण्याचा प्रयत्न

राहुल गांधी यांचा कोलकात्यातील रुग्णालय प्रशासनावर आरोप

पीटीआय, नवी दिल्ली

कोलकाता येथे प्रशिक्षणार्थी डॉक्टरांच्या बलात्कार आणि हत्येवरून ठिकठिकाणी आंदोलने सुरू आहेत. दरम्यान पीडितेला न्याय देण्याऐवजी रुग्णालय आणि स्थानिक प्रशासनाकडून आरोपीला वाचवण्याचा प्रयत्न सुरू असल्याचा गंभीर आरोप लोकसभेतील विरोधी पक्षनेते राहुल गांधी यांनी बुधवारी केला. डॉक्टरांच्या बलात्कार आणि हत्येच्या भोषण घटनेने संपूर्ण देश हादरला आहे. या अमानवी क्रत्याने डॉक्टर आणि महिलांमध्ये अस्पृक्षिततेचे वातावरण असल्याचेही राहुल गांधी यांनी म्हटले आहे.

पीडितेला न्याय देण्याऐवजी आरोपीला वाचवण्याचा प्रयत्न रुग्णालय आणि स्थानिक प्रशासनाच्या भूमिकेवर गंभीर प्रश्न निर्माण करतो, असे राहुल गांधी यांनी 'एक्स'वरील संदेशात म्हटले. या घटनेने विचार करायला भाग पाडले आहे. वैद्यकीय महाविद्यालयासारख्या ठिकाणी डॉक्टरच सुरक्षित नसतील तर पालक आपल्या मुलींना बाहेर शिक्षणासाठी कसे पाठवतील, निर्भया प्रकरणांनंतर केलेले कठोर कायदेही असे गुन्हे रोखण्यात यशस्वी का झाले नाहीत, असे प्रश्न राहुल गांधी यांनी उपस्थित केले आहेत.

'हाथरस ते उन्नाव आणि कटुआ ते कोलकाताच्या घटनेवरून महिलांवरील अत्याचार सातत्याने वाढत असल्याचे समोर येते. अशा घटनांवर प्रत्येक राजकीय पक्ष,



आंदोलनाने आरोग्य सेवा वेटीस

● पश्चिम बंगालमधील कनिष्ठ डॉक्टरांनी बुधवारी सहाय्या दिवशी सरकारी वैद्यकीय महाविद्यालय आणि रुग्णालयात हत्येच्या निषेधार्थ काम बंद ठेवले. या सुरू असलेल्या आंदोलनाचा मोठा परिणाम आरोग्य सेवांवर झाला. परिणामी सर्व सरकारी रुग्णालयांच्या बाह्यरुग्ण विभागांमध्ये (ओपीडी) रुग्णांच्या लांबच लांब रांगा लागल्या होत्या.

● आंदोलक कनिष्ठ डॉक्टरांनी दंडाधिकाऱ्यांमार्फत या प्रकरणाची चौकशीची आणि आंदोलक ज्युनियर डॉक्टरांतर्फे महिला डॉक्टरांच्या हत्येची दंडाधिकारी चौकशी आणि आर.जी. कार वैद्यकीय महाविद्यालय आणि रुग्णालयातील वरिष्ठ अधिकाऱ्यांना काढून टाकण्याच्या मागणीसाठी तीव्र आंदोलन सुरू आहे.

समाजातील प्रत्येक घटकाला गंभीर चर्चा करून ठोस पावले उचलावी लागतील. पीडित कुटुंबीयांच्या वेदनांमध्ये मी पाठीशी उभा आहे. त्यांना कोणत्याही परिस्थितीत न्याय मिळाला पाहिजे आणि दोषींना अशी शिक्षा मिळावी की ते समाजात उदाहरण म्हणून काम करेल,' असेही राहुल गांधी यांनी म्हटले आहे. तत्पूर्वी या हत्येचा तपास कोलकाता पोलिसांकडून केंद्रीय अन्वेषण ब्युरोकडे (सीबीआय) हस्तांतरित करण्याचे आदेश कोलकाता उच्च न्यायालयाने मंगळवारी दिले आहेत.

आसाममधील 'तो' निर्णय मागे गुवाहाटी : आसाममधील सिलचर रुग्णालयाने बुधवारी महिला डॉक्टरांच्या वेदनांमध्ये मी पाठीशी उभा आहे. वेळी एकट्याने जाणे टाळण्यास सांगणारा निर्णय मागे घेतला आहे. कोलकाता येथील घटनेच्या पार्श्वभूमीवर रुग्णालयाचे प्राचार्य आणि मुख्य अधीक्षक डॉ. भास्कर गुप्ता यांनी हा निर्णय जारी केला होता. आधी जाहीर केलेला निर्णय रद्द केला असून, या संदर्भात लवकरच नवीन निर्णय जाहीर केला जाईल, असे डॉ. गुप्ता यांनी सांगितले.



दिल्लीच्या इंदिरा गांधी आंतरराष्ट्रीय विमानतळावरील नवीन टर्मिनल-१ येत्या १७ ऑगस्टपासून सेवेत येणार आहे. २८ जून रोजी छत दुर्घटनेमुळे जुने टर्मिनल-१ तात्पुरते बंद करण्यात आले होते. येथील विमानवाहतूक टर्मिनल २ आणि ३ वर वळवण्यात आली होती. अत्याधुनिक टर्मिनल-१ ची प्रवासी क्षमता लक्षणीयरीत्या वाढण्यात आली आहे. प्रवाशांना येथे अत्याधुनिक सुविधा मिळणार आहेत.

हॅरिस यांचा जाहिरातींवर जोर

वॉशिंग्टन : अमेरिकेच्या राष्ट्राध्यक्षपदाच्या उमेदवार कमला हॅरिस यांच्या निवडणूक प्रचारासाठी जाहिरातींवर पुढील तीन आठवड्यात ९० दशलक्ष डॉलर खर्च केले जाणार आहेत. हॅरिस यांची लढत माजी राष्ट्राध्यक्ष आणि रिपब्लिकन पक्षाचे उमेदवार डोनाल्ड ट्रम्प यांच्याशी होत आहे.

अध्यक्षपदाची ही निवडणूक नोव्हेंबरमध्ये होत आहे. मतदानाच्या दिवसापर्यंतच्या साधारण दोन-अडीच महिन्यांच्या कालावधीत मतदारांना संदेश पाठवण्यासाठी केलेली ही आतापर्यंतची सर्वात महागडी प्रचारांमोहीम आहे. गेल्या महिन्यात जो बायडेन यांच्याऐवजी हॅरिस यांना उमेदवारी जारी झाल्यानंतर तत्काळ ५० दशलक्ष डॉलर्सच्या जाहिरातीची नोंदणी करण्यात आली होती.

केजरीवाल यांना अंतरिम जामीन देण्यास नकार

सीबीआयला उत्तर देण्याचेही आदेश

नवी दिल्ली : दिल्लीचे मुख्यमंत्री अरविंद केजरीवाल यांना अंतरिम जामीन देण्यास सर्वोच्च न्यायालयाने बुधवारी नकार दिला. कथित अबकारी धोरण घोटाळाप्रकरणी (मद्य घोटाळा) केंद्रीय गुन्हे अन्वेषण विभागाने हा भ्रष्टाचाराचा खटला दाखल केला आहे. या प्रकरणी केजरीवाल यांच्या अटकेला आव्हान देणाऱ्या याचिकेवर न्यायालयाने तपास यंत्रणेकडून उत्तर मागितले आहे. या प्रकरणी पुढील सुनावणी २३ ऑगस्ट रोजी होणार आहे.

न्या. सूर्यकांत आणि उज्ज्वल भूयान यांच्या खंडपीठासमोर ही सुनावणी झाली. केजरीवाल यांच्या वतीने ज्येष्ठ वकील अभिषेक सिंघवी यांनी युक्तिवाद केला. आर्थिक गैरव्यवहार प्रकरणत केजरीवाल यांना तीन वेळा अंतरिम जामीन मिळाला होता. हे प्रकरण कथित मद्य घोटाळाप्रशीही जोडले गेले होते. आर्थिक गैरव्यवहार प्रतिबंधक कायदांतर्गत (पीएमएलए) खटल्यांमध्ये जामीन मंजूर करण्यासाठी कठोर अटी असूनही जामीन मिळाला होता. भ्रष्टाचार प्रतिबंधक कायद्यात जामिनासाठी कठोर अटी नसल्याने त्यांना नियमित जामीन नाकारला जाऊ शकत नाही, असा युक्तिवाद सिंघवी यांनी केला. सर्वोच्च न्यायालयाने १० मे आणि १२ जुलै रोजी अंतरिम जामीन मंजूर केला होता, तर सत्र न्यायालयाने २० जून रोजी नियमित जामीन मंजूर केला होता, याकडे सिंघवी यांनी न्यायालयाचे लक्ष वेधले.

नवी दिल्ली : नीट सुपर स्पेशलिटी प्रवेश परीक्षा न घेण्याच्या राष्ट्रीय वैद्यकीय आयोगाच्या (एनएमसी) निर्णयाला आव्हान देणारी याचिका सर्वोच्च न्यायालयाने बुधवारी

'नीट'बाबतची आव्हान याचिका फेटाळली

फेटाळली. सरन्यायाधीश डी. वाय. चंद्रचूड आणि न्या. जे.बी. पारडीवाला आणि न्या. मनोज मिश्रा

यांच्या खंडपाळाने सुनावणी घेतली. परीक्षेच्या वेळापत्रकाशी कोणतीही छेडछाड करण्यास न्यायालयाने

नकार दिला. राष्ट्रीय वैद्यकीय आयोगाचा निर्णय न्याय्य असल्याचे मत खंडपीठातने मांडले. राहुल

बलवान यांच्यासह १३ डॉक्टरांनी ही याचिका दाखल केली होती. याप्रकरणी सर्वोच्च न्यायालयाने १९ जुलै रोजी राष्ट्रीय वैद्यकीय आयोगाला नोटीस बजावली होती.

GLENMARK PHARMACEUTICALS LIMITED									
Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026; Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off. Western Express Highway, Andheri (E), Mumbai - 400099. Phone No: +91 22 4018 9999 Fax No: +91 22 4018 9986; Website: www.glenmarkpharma.com; Email: complianceofficer@glenmarkpharma.com; CIN: L24299MH1977PLC019982									
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2024									
(All amounts in million of Indian Rupees, unless otherwise stated)									
Sr. No.	Particulars	Standalone				Consolidated			
		Quarter ended 30/06/2024 (Unaudited)	Quarter ended 31/03/2024 (Refer note 7)	Quarter ended 30/06/2023 (Unaudited)	Year ended 31/03/2024 (Audited)	Quarter ended 30/06/2024 (Unaudited)	Quarter ended 31/03/2024 (Refer note 7)	Quarter ended 30/06/2023 (Unaudited)	Year ended 31/03/2024 (Audited)
I	Revenue from operations	22,968.75	20,771.32	20,980.62	76,497.61	32,233.02	30,160.07	29,984.72	1,16,354.56
	(a) Net sales	326.62	710.91	463.22	2,413.58	208.84	469.45	375.94	1,776.41
	(b) Other operating income	23,295.37	21,482.23	21,443.84	78,911.19	32,441.86	30,629.52	30,360.66	1,18,130.97
	Total revenue from operations	556.48	7,862.70	11,880.24	493.61	314.92	7,731.65	197.22	8,399.94
II	Other income	23,851.85	29,344.93	21,937.45	90,591.43	32,756.78	38,361.17	30,557.88	1,26,530.91
III	Total income (I + II)	6,481.09	6,854.51	7,967.56	29,904.11	6,857.74	7,543.09	8,302.54	31,578.22
IV	Expenses	889.85	816.58	821.71	3,227.82	3,600.26	2,108.04	4,184.25	14,511.70
	(a) Cost of materials consumed	569.24	(21.20)	(230.84)	(1,030.70)	642.82	304.15	(608.82)	(1,956.22)
	(b) Purchases of stock-in-trade	3,844.03	3,377.45	3,344.66	14,347.75	7,104.40	7,009.55	6,812.73	28,681.43
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	153.49	833.85	619.34	2,771.10	395.82	1,485.59	1,116.08	5,159.69
	(d) Employee benefits expense	530.87	524.01	487.52	2,021.62	1,177.89	1,513.37	1,420.40	5,199.61
	(e) Finance costs	5,200.14	5,480.41	4,690.79	20,045.58	8,354.51	8,621.26	7,296.44	33,362.53
	(f) Depreciation, amortisation and impairment expense	17,668.71	17,865.61	17,700.74	71,287.28	28,133.44	28,585.05	28,523.62	1,17,156.41
	(g) Other expenses	6,183.14	11,479.32	4,236.71	19,304.15	4,623.34	9,776.12	2,034.26	9,374.50
V	Profit/(loss) before exceptional items and tax (III - IV)	(51,469.13)	316.29	3,162.99	(50,703.31)	-	4,467.85	520.23	9,009.55
VI	Profit/(loss) before tax from continuing operations (V - VI)	6,183.14	62,948.45	3,920.42	70,007.46	4,623.34	5,308.28	1,514.03	364.95
VII	Tax expense :	1,079.84	10,553.79	385.65	10,499.92	1,468.82	10,581.74	567.23	11,555.52
	Current tax	565.99	6,257.71	818.21	7,834.63	(247.86)	7,112.99	570.02	7,517.93
	Deferred tax	4,537.31	46,136.95	2,716.56	51,672.91	3,402.38	(12,386.45)	376.78	(18,308.50)
VIII	Profit/(loss) after tax for the period from continuing operations (VII - VIII)	-	-	-	-	(0.29)	40.10	231.94	681.46
IX	Profit/(loss) for the period from continuing operations attributable to:	-	-	-	-	3,402.67	(12,426.55)	144.84	(18,989.96)
	- Non-controlling interests	-	-	-	-	-	40.10	144.84	5,326.92
	- Owners of the Company	4,537.31	46,136.95	2,716.56	51,672.91	-	(12,426.55)	144.84	(18,989.96)
XI	Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-	-	-
XII	Tax expense of discontinued operations :	-	-	-	-	-	72.73	435.99	1,284.32
	Current tax	-	-	-	-	-	(5.69)	29.55	69.32
	Deferred tax	-	-	-	-	-	243.76	1,354.50	3,973.28
XIII	Profit/(loss) after tax for the period from discontinued operations (XI - XII)	-	-	-	-	-	-	-	-
XIV	Profit/(loss) for the period from discontinued operations attributable to:	-	-	-	-	-	243.76	1,354.50	3,973.28
	- Non-controlling interests	-	-	-	-	-	-	-	-
	- Owners of the Company	-	-	-	-	-	243.76	1,354.50	3,973.28
XV	Profit/(loss) after tax for the period from continuing and discontinued operations (IX + XIII)	4,537.31	46,136.95	2,716.56	51,672.91	3,402.38	(12,142.69)	1,731.28	(14,335.22)
XVI	Profit/(loss) for the period from continuing and discontinued operations attributable to:	-	-	-	-	(0.29)	40.10	231.94	681.46
	- Non-controlling interests	-	-	-	-	3,402.67	(12,182.79)	1,499.34	(15,016.68)
	- Owners of the Company	4,537.31	46,136.95	2,716.56	51,672.91	-	40.10	231.94	(18,009.55)
XVII	Other comprehensive income from continuing operations	(12.52)	(9.74)	(7.50)	(73.14)	(7.01)	(94.10)	(5.52)	(163.06)
	(i) Items that will not be reclassified to profit or loss	4.37	9.44	2.23	25.56	2.79	26.65	2.23	42.75
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-	60.50	846.57	(564.37)	(399.03)
	(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	(1.36)	(20.13)	6.80	(79.97)
XVIII	Total comprehensive income from continuing operations for the period/ year	4,529.16	46,136.65	2,711.29	51,625.33	3,457.30	(11,627.47)	(184.08)	(18,907.81)
XIX	Other comprehensive income from discontinued operations for the period/ year	-	-	-	-	-	(0.19)	(0.73)	(56.23)
XX	Total comprehensive income from discontinued operations for the period/ year (XIII + XIX)	-	-	-	-	-	243.57	1,353.77	3,917.05
XXI	Other comprehensive income for the period/ year from continuing and discontinued operation (XVII + XIX)	(8.15)	(0.30)	(5.27)	(47.58)	54.92	758.79	(561.59)	(655.53)
XXII	Total comprehensive income for the period/ year from continuing and discontinued operation (XVIII + XX)	4,529.16	46,136.65	2,711.29	51,625.33	3,457.30	(11,383.89)	1,169.69	(14,990.76)
XXIII	Total comprehensive income attributable to:	-	-	-	-	(0.26)	40.22	231.98	672.00
	- Non-controlling interests	-	-	-	-	3,457.56	(11,424.11)	937.71	(15,662.76)
	- Owners of the Company	4,529.16	46,136.65	2,711.29	51,625.33	-	40.22	231.98	672.00
XXIV	Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.19	282.19	282.19	282.19	282.19	282.19	282.19	282.19
XXV	Other equity (other than revaluation reserve)	-	-	-	-	-	-	-	-
XXVI	Earning per share for continuing operations (EPS) (not annualised except for the year ended 31 March)	12.06	(44.04)	0.51	(67.30)	12.06	(44.04)	0.51	(67.30)
	Basic (in Rupees)	12.06	(44.04)	0.51	(67.30)	12.06	(44.04)	0.51	(67.30)
	Diluted (in Rupees)	-	0.86	4.80	14.08	-	0.86	4.80	14.08
XXVII	Earning per share for discontinued operations (EPS) (not annualised except for the year ended 31 March)	-	0.86	4.80	14.08	-	0.86	4.80	14.08
	Basic (in Rupees)	-	0.86	4.80	14.08	-	0.86	4.80	14.08
	Diluted (in Rupees)	-	0.86	4.80	14.08	-	0.86	4.80	14.08
XXVIII	Earning per share for continuing and discontinued operations (EPS) (not annualised except for the year ended 31 March)	16.08	163.50	9.63	183.13	12.06	(43.17)	5.31	(53.22)
	Basic (in Rupees)	16.08	163.50	9.63	183.13	12.06	(43.17)	5.31	(53.22)
	Diluted (in Rupees)	-	-	-	-	-	-	-	-

Notes:

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- The above results were reviewed by the Audit Committee at its meeting held on 13th August, 2024 and approved by the Board of Directors at their meetings held on 14th August, 2024. The results for the quarter ended 30th June, 2024 presented were subjected to a 'Limited Review' by statutory auditors of the Company who have issued an unmodified report on the said results.
- The Chief Operating Decision Maker ('CODM') reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
- As at 30th June, 2024, pursuant to Employee Stock Options Scheme 2016, 37,779 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
- Exceptional items:
 - Standalone: 31.03.2024
 - Exceptional item in the standalone result for the quarter and year ended 31 March 2024 Rs. 51,469.13 million (gain) and Rs 50,703.31 million (gain) respectively, primarily comprises of stake sale (net of expenses) in Glenmark Lifescience Ltd, remediation, legal, inventory provision and others.
 - Pursuant to Board approval dated 21 September 2023, the Company entered into share purchase agreement with Nirma Limited (the 'Buyer') for the sale of 91,895,379 equity shares representing 75.00% of the current issued and paid-up equity share capital of Glenmark Life Sciences Limited ('GLS'), a subsidiary of the Company, to the Buyer at a price of INR 615/- per share, aggregating to INR 56,515 million (subject to adjustments as agreed among the parties), in accordance with the terms of the share purchase agreement dated 21 September 2023 among the Company, GLS and the Buyer. Accordingly, 91,895,379 equity shares representing 75% of the current issued and paid-up equity share capital of the GLS, were transferred by the Company to Buyer as follows:
 - A. On 6 March, 2024, 6,73,89,944 equity shares, representing 55% of the issued and paid-up equity share capital of the GLS were transferred by the Company to Buyer.
 - B. On 12 March, 2024, 2,45,05,435 equity shares, representing 20% of the issued and paid-up equity share capital of the GLS were transferred by the Company to Buyer.
 - As required by Ind-AS 105 'Asset Held for Sale and Discontinuing Operations,' GLS had been classified as discontinued operations after eliminating intercompany transactions and relevant disclosures made in the financial results.
 - 30.06.2023
 - Exceptional item of Rs.316.29 in the standalone result for the quarter comprises of remediation cost of manufacturing sites in India.
 - Consolidated: 31.03.2024
 - Exceptional item in the Consolidated result for the quarter and full year ended 31 March 2024 is Rs. 4,467.85 million (loss) and Rs 9,009.55 million (loss) respectively primarily comprises of stake sale (net of expenses) in Glenmark Lifescience Ltd, impairment of certain block at Monroe facility, De-prioritisation of certain intangibles, settlement & legal cost, remediation cost and working capital adjustments.
 - The US subsidiary Glenmark Pharmaceuticals Inc., USA ('Company') has entered into an agreement with the U.S. Department of Justice, Antitrust Division (DOJ) on 22 August, 2023 to resolve all of its court proceedings with the DOJ involving historical pricing practices relating to the generic drug pravastatin between 2013 and 2015. The Company has entered into a three-year Deferred Prosecution Agreement, and if the Company adheres to the terms of the agreement, including the payment of \$30 million, payable in six instalments, the DOJ will dismiss the pending Superseding Indictment.
 - The US subsidiary Glenmark Pharmaceuticals Inc., USA ('Company') is likely to enter into an agreement with the U.S. Department of Justice, Antitrust Division (DOJ), subject to all necessary approvals being in place, to the extent of \$30 million (including related cost), to resolve all of its Civil court proceedings with the DOJ. Due to the non-recurring nature of the provision, the Company has classified this provision as an exceptional item in the financial statements for the quarter and year ended 31 March 2024. Pursuant to all necessary approvals and on finalisation of settlement agreements, the crystallized liability will be accounted after adjusting the provisions in this respect.